Day: May 14, 2024

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) — MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG”, or the “Company”) today announced that it has filed a preliminary short form base shelf prospectus (the “Preliminary Shelf Prospectus”) with the securities commissions in all of the provinces and territories of Canada. A corresponding registration statement on Form F-10 will be filed with the United States Securities and Exchange Commission (the “SEC”) under the United States Securities Act of 1933, as amended and the U.S./Canada Multijurisdictional Disclosure System (the “Registration Statement”) at the time of filing of the final short form base shelf prospectus (the “Final Shelf Prospectus” and, together with the Preliminary Shelf Prospectus, the “Prospectus”). Upon the issuance of a receipt for the Final Shelf Prospectus...

TORONTO, May 14, 2024 (GLOBE NEWSWIRE) — Centerra Gold Inc. (TSX: CG) (NYSE: CGAU) (“Centerra” or the “Company”) announces the results of its 2024 Annual Meeting of Shareholders (the “Meeting”) held on May 14, 2024. A total of 153,055,848 shares, representing 71.13% of common shares issued and outstanding, were represented at the Meeting. Detailed voting results are outlined below. Election of Directors Each of the nominee directors listed in Centerra’s management information circular dated April 2, 2024, was elected.  Votes For % Votes For Votes Against % Votes AgainstWendy Kei 148,064,693 99.42% 867,037 0.58%Craig MacDougall 148,659,809 99.82% 271,922 0.18%Michael S. Parrett 142,540,384 95.71% 6,391,347 4.29%Jacques Perron 146,616,832 99.11% 1,314,897 0.89%Sheryl K. Pressler 147,378,974 98.96% 1,552,756 1.04%Paul...

– Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024 COPENHAGEN, Denmark, May 14, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food and Drug Administration (FDA) notified the Company that information submitted in response to the FDA’s ongoing review of the New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism constituted a major amendment to the NDA. Accordingly, the FDA has extended the PDUFA target action date by three months, to August 14, 2024, to provide time for a full review of the submission. “We have responded to all requests received to date from FDA and will work with the agency as they continue their review of our NDA,” said Jan Mikkelsen, Ascendis...

Voltalia launches its third employee share purchase plan Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces the launch of its third employee share purchase plan Through its third employee share purchase plan, Voltalia offers a new opportunity for eligible employees to participate in the company’s growth and success. This plan reflects Voltalia’s firm commitment to attract and retain the talents that embodie its mission and contribute to its value creation. With this operation, Voltalia enters a new stage after the introduction of the profit-sharing scheme at the end of 2017, followed by its first year of application in 2018 and the launch of the employee share purchase plan in spring 2019 and 2022. The previous employee shareholding plans had enjoyed strong support from...

Paris, 14 May 2024 Air France-KLM announces the successful issuance of new bonds for a total aggregate amount of €650 million Air France-KLM (the “Company”) has successfully placed new bonds today, for a total nominal amount of €650 million with a 5-year maturity and a coupon of 4.625% (the “New Notes”) under its Euro 4,500,000,000 Euro Medium Term Note Programme. The New Notes are expected to be rated BBB- by Fitch and BB+ by S&P. Strong investor demand, with an orderbook above €2.8 billion that covered c.4.3x the size of the bonds, is a testament to investors’ confidence in Air France-KLM. The Company announced on 13 May 2024 the launch of a tender offer to repurchase the following two series of existing notes in cash:€750,000,000 1.875 per cent notes due 16 January 2025 (ISIN: FR0013477254) (of which €750,000,000 is currently...